This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Petersen, P. M. Articles by Skakkebæk, N. E. Search for Related Content PubMed PubMed Citation Articles by Petersen, P. M. Articles by Skakkebæk, N. E. Social Bookmarking                            What's this?

Impaired Testicular Function in Patients With Carcinoma-In-Situ of the Testis

From the Department of Growth and Reproduction and Department of Oncology, Finsencenter, Copenhagen University Hospital, Rigshospitalet, Copenhagen; Department of Oncology, Herlev Hospital, University of Copenhagen, Copenhagen; and Department of Gynaecology, Hillerød Sygehus, Hillerød, Denmark.

Address reprint requests to Peter Meidahl Petersen, MD, Department of Growth and Reproduction, Copenhagen University Hospital, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark

PURPOSE: To elucidate the biologic association between germ cell neoplasia and testicular dysfunction, through investigation of Leydig cell function and semen quality in men with carcinoma-in-situ (CIS) of the testis.

PATIENTS AND METHODS: We examined two groups of men, unilaterally orchidectomized for testicular cancer. Biopsy of the contralateral testis had showed CIS in a group of 24 patients and no evidence of CIS in the other group of 30 patients. Semen quality and serum levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were compared in these two groups of men after orchidectomy but before further treatment for testicular cancer.

RESULTS: Significantly higher LH levels (median, 8.1 IU/L v 4.8 IU/L; P < .001) and generally lower testosterone levels (median, 12.5 nmol/L v 15.5 nmol/L; P = .13) were found in the CIS group. The proportion of patients with Leydig cell dysfunction was higher in the group of patients with CIS (11 of 24) than in the group of patients without (two of 30) (P = .01). Sperm concentration and total sperm count were significantly lower (P < .001) in patients with CIS (median, 0.03 x 10⁶/mL and 0.10 x 10⁶, respectively) than in patients without (median, 9.1 x 10⁶/mL and 32 x 10⁶, respectively), whereas the levels of FSH were significantly higher (P < .001) in the former group of men (median, 19.6 IU/L v 9.0 IU/L).

CONCLUSION: Not only spermatogenesis but also Leydig cell function is impaired in testes with CIS. This impairment could be due to common factors in the pathogenesis of germ cell neoplasm and testicular dysfunction. Alternatively, CIS cells may have a negative impact on Leydig cell function.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer Medical Treatment of Advanced Testicular Cancer JAMA, February 13, 2008; 299(6): 672 - 684. [Abstract] [Full Text] [PDF]

				C. E. Hoei-Hansen, E. Rajpert-De Meyts, G. Daugaard, and N. E. Skakkebaek Carcinoma in situ testis, the progenitor of testicular germ cell tumours: a clinical review Ann. Onc., June 1, 2005; 16(6): 863 - 868. [Abstract] [Full Text] [PDF]

				M. Samson, F. V. Peale Jr., G. Frantz, N. Rioux-Leclercq, E. Rajpert-De Meyts, and N. Ferrara Human Endocrine Gland-Derived Vascular Endothelial Growth Factor: Expression Early in Development and in Leydig Cell Tumors Suggests Roles in Normal and Pathological Testis Angiogenesis J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 4078 - 4088. [Abstract] [Full Text] [PDF]

				A.-M. Andersson, N. Jorgensen, L. Frydelund-Larsen, E. Rajpert-De Meyts, and N. E. Skakkebaek Impaired Leydig Cell Function in Infertile Men: A Study of 357 Idiopathic Infertile Men and 318 Proven Fertile Controls J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3161 - 3167. [Abstract] [Full Text] [PDF]

				L. Gandini, F. Lombardo, P. Salacone, D. Paoli, A. P. Anselmo, F. Culasso, F. Dondero, and A. Lenzi Testicular cancer and Hodgkin's disease: evaluation of semen quality Hum. Reprod., April 1, 2003; 18(4): 796 - 801. [Abstract] [Full Text] [PDF]

				P. M. Petersen, A. Giwercman, G. Daugaard, M. Rorth, J. H. Petersen, N. E. Skakkebaek, S. W. Hansen, and H. von der Maase Effect of Graded Testicular Doses of Radiotherapy in Patients Treated for Carcinoma-In-Situ in the Testis J. Clin. Oncol., March 15, 2002; 20(6): 1537 - 1543. [Abstract] [Full Text] [PDF]

				R. Jacobsen, E. Bostofte, G. Engholm, J. Hansen, N. E. Skakkebak, and H. Moller Fertility and offspring sex ratio of men who develop testicular cancer: a record linkage study Hum. Reprod., September 1, 2000; 15(9): 1958 - 1961. [Abstract] [Full Text] [PDF]